Study of alisertib and paclitaxel for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with small cell lung cancer (SCLC)
- You have already had at least one platinum-based chemotherapy and one immunotherapy (like a PD-1 or PD-L1 inhibitor)
- You may have had up to one additional cancer treatment, for a total of no more than two prior treatments
- Your cancer can be measured on scans (has at least one tumor that can be seen and tracked)
- You have not been treated before with a drug like alisertib that targets aurora kinase A
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as the first treatment for small-cell lung cancer that has spread. It is designed for older patients or those who cannot tolerate standard intensive chemotherapy, with the goal of controlling the cancer while being gentler on the body.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hear when a new Small Cell Lung Cancer ( SCLC ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.